SciTech Development | Fenretinide | nanoFenretinide | Michigan, USA
SciTech is a clinical stage, specialty pharmaceutical company that has developed a proprietary nanoparticle delivery platform (SciTech Drug Delivery Platform, SDP) to maximize the bioavailability of water-insoluble therapeutics, while maintaining or improving safety profiles. SciTech's first engineered therapeutic using the delivery platform is our patented lead drug candidate ST-001 nanoFenretinide, a combination of SDP with the promising cancer drug fenretinide. ST-001 nanoFenretinide is a nano-particle formulation that should enable the safe, rapid, intravenous (IV) delivery of high-dose fenretinide. Sub-therapeutic dose levels lead to insufficient delivery to the cancer cell, and unacceptable toxicity to patients. SOLUTION: AN EFFECTIVE DELIVERY PLATFORM FOR ST-001 NANOFENRETINIDE. SciTech’s Drug Delivery Platform (SDP), the biomimetic phospholipid matrix which has enabled fenretinide, should be capable of delivering other drugs with similar properties, including non-cancer drugs. SDP should be capable of delivering drugs alone or as a combination therapy with other drugs or treatment regimens (radiation, surgery). Unique ST-001 nanoFenretinide Formulation Expected drug delivery of therapeutic doses - with anticipated safety & effectiveness; Patented.
This company is:
Verified
Lead Drug Product | ST-001 nanoFenretinide | SciTech Development
SciTech is Advancing Cancer Treatment Through Safer Drug Delivery - SciTech Development is a Specialty Pharmaceutical Company dedicated to advancing cancer treatment with a revolutionary new Drug Delivery Platform (SDP) that engineers new therapeutics for broader and better clinical outcomes. Our patented and lead drug candidate ST-001 nanoFenretinide is a combination of SDP with the promising cancer drug, fenretinide.
Verified
Product Pipeline | SciTech Development | Fenretinide | nanoFenretinide
SciTech's fenretinide & nanoFenretinide drug product pipeline for the treatment of T-cell non-Hodgkin's lymphoma (NHL), metastatic breast cancer (MBC), neuroblastoma, T-cell acute lymphoblastic leukemia (T-ALL), topical formulations for the treatment of various skin cancers and bed sores & other.
Verified
Technology | Fenretinide | nanoFenretinide | SciTech Development
SciTech’s lead drug candidate ST-001 nanoFenretinide is a patented small molecule nano-particle formulation of fenretinide targeting a broad range of cancers: lymphomas, lung cancer, prostate, pancreatic, breast, colon and other cancers where historic data suggests a likely response to fenretinide.
View all products
Keywords
Industries
Where is SciTech Development LLC located?
The company SciTech Development LLC is located in Grosse Pointe Farms, Michigan, United States. It's worth noting that the company may has more corporate locations
In which industries does SciTech Development LLC mainly work?
The company SciTech Development LLC has it's main focus in the industries of Pharmaceuticals
Nanotech Pharma Inc.
United States
1-10 Employees
2018
View
NanoMedical Systems
United States
11-50 Employees
2006
View
Co-D Therapeutics
United States
1-10 Employees
2012
View
Pdx Pharmaceuticals
United States
11-50 Employees
2010
View
N1 Life
United States
1-10 Employees
2019
View
Integrated Nanotherapeutics Inc.
Canada
1-10 Employees
View
NanOlogy
United States
1-10 Employees
2015
View
Oncology Pharma
United States
1993
View
Topics which have been searched by others and may be interesting for you: